The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway

American Journal of Medical Genetics, Part A

Volumn 170, Issue 8, 2016, Pages 1959-1966

  Stevenson, David A ^a   Schill, Lisa ^b   Schoyer, Lisa ^b   Andresen, Brage S ^c   Bakker, Annette ^d   Bayrak Toydemir, Pinar ^e   Burkitt Wright, Emma ^f   Chatfield, Kathryn ^g   Elefteriou, Florent ^h   Elgersma, Ype ⁱ   Fisher, Michael J ^j   Franz, David ^k   Gelb, Bruce D ^l   Goriely, Anne ^m   Gripp, Karen W ⁿ   Hardan, Antonio Y ^a   Keppler Noreuil, Kim M ^o   Kerr, Bronwyn ^f   Korf, Bruce ^p   Leoni, Chiara ^q   McCormick, Frank ^r   Plotkin, Scott R ^s   Rauen, Katherine A ^t   Reilly, Karlyne ^r   Roberts, Amy ^u   Sandler, Abby ^r   Siegel, Dawn ^v   Walsh, Karin ^w   Widemann, Brigitte C ^r   more..

^a STANFORD UNIVERSITY   (United States)

^b RASopathies Network   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Children's Tumor Foundation   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF COLORADO   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k UNIVERSITY OF CINCINNATI   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^o NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^q FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^r NATIONAL CANCER INSTITUTE   (United States)

^s MASSACHUSETTS GENERAL HOSPITAL   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u BOSTON CHILDREN S HOSPITAL   (United States)

^v MEDICAL COLLEGE OF WISCONSIN   (United States)

^w GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

more..

Author keywords

cancer; clinical trials; experimental models; rare disorders; Ras MAPK; RASopathy

Indexed keywords

BIOMARIN; DABRAFENIB; GAMMA SECRETASE INHIBITOR; GROWTH HORMONE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROFIBROMIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAPAMYCIN; RAS PROTEIN; SELUMETINIB; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ACHONDROPLASIA; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER RISK; CARDIOFACIOCUTANEOUS SYNDROME; CHRONIC PAIN; COGNITIVE DEFECT; CONGENITAL HEART DISEASE; COSTELLO SYNDROME; DESMOID TUMOR; DISORDERS OF HIGHER CEREBRAL FUNCTION; EMBRYO MORTALITY; GENETIC DISORDER; GERMLINE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MELANOMA; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS TYPE 2; NONHUMAN; NOONAN SYNDROME; ONCOGENE H RAS; ONCOGENE K RAS; PLEXIFORM NEUROFIBROMA; PRIORITY JOURNAL; RAS MITOGEN ACTIVATED PROTEIN KINASE TRANSDUCTION PATHWAY; RASOPATHY; SHORT STATURE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; CLINICAL TRIAL (TOPIC); FAMILY; FINANCIAL MANAGEMENT; GENETIC DISEASES, INBORN; GENETICS; INTERSECTORAL COLLABORATION; METABOLISM;

CAPITAL FINANCING; CLINICAL TRIALS AS TOPIC; FAMILY; GENETIC DISEASES, INBORN; HUMANS; INTERSECTORAL COLLABORATION; MITOGEN-ACTIVATED PROTEIN KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84966292091     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.37723     Document Type: Article

References (16)

1. Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF Jr, Rowland KM Jr, Nair S, Tschetter LK, Fitch TR. 2004. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II trial. J Clin Oncol 22:4944–4950.
2. Costa RM, Silva AJ. 2002. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J Child Neurol 17:622–626. discussion 627–629, 646–651.
3. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. 2012. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16:S17–S27.
4. Gelb BD, Roberts AE, Tartaglia M. 2015. Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog Pediatr Cardiol 39:13–19.
5. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. 2013. Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 10:390–399.
6. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. 2013. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123:340–347.
7. Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG. 2015. PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet Part A 167A:287–295.
8. Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C, Kohlhase J, Pauli S, Wildhardt G, Kutsche K, Auber B, Christmann A, Bachmann N, Mitter D, Cremer FW, Mayer K, Daumer-Haas C, Nevinny-Stickel-Hinzpeter C, Oeffner F, Schlüter G, Gencik M, Überlacker B, Lissewski C, Schanze I, Greene MH, Spix C, Zenker M. 2015. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer 112:1392–1397.
9. McCormick F. 2015. KRAS as a therapeutic target. Clin Cancer Res 21:1797–1801.
10. Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC. 2013. Achieving consensus for clinical trials: The REiNS international collaboration. Neurology 81:S1–S5.
11. Prendiville TW, Gauvreau K, Tworog-Dube E, Patkin L, Kucherlapati RS, Roberts AE, Lacro RV. 2014. Cardiovascular disease in Noonan syndrome. Arch Dis Child 99:629–634.
12. Rauen KA. 2013. The RASopathies. Annu Rev Genomics Hum Genet 14:355–369.
13. van der Vaart T, Rietman AB, Plasschaert E, Legius E, Elgersma Y, Moll HA, NF1-SIMCODA Study Group. 2016. Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1. Neurology 86:154–160.
14. Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. 2015. K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell 163:1237–1251.
15. Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM. 2014a. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol 16:707–718.
16. Widemann B, Marcus L, Fisher M, Weiss B, Kim A, Dombi E, Baldwin A, Whitcomb P, Martin S, Gillespie A, Doyle A. 2014b. Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). J Clin Oncol 32:5s(suppl; abstr 10018).